Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Pembrolizumab in Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (rrPMBCL): Updated Analysis of the Keynote-170 Phase 2 Trial

Pier Luigi Zinzani, MD, Catherine Thieblemont, MD PhD, Vladimir Melnichenko, Krimo Bouabdallah, Jan Walewski, MD PhD, Alejandro Majlis, MD, Laura Fogliatto, MD, Dolores Caballero, MD PhD, Beth Christian, MD, Zafer Gulbas, MD, Muhit Özcan, MD, Gilles Andre Salles, MD PhD, Margaret A. Shipp, MD, Arkendu Chatterjee, Robert J Orlowski, Arun Balakumaran, MD PhD, Philippe Armand, MD PhD

Blood (2017) 130 (Supplement 1): 2833.

https://doi.org/10.1182/blood.V130.Suppl_1.2833.2833

Published: 2017

Journal Articles

Randomized Phase 2 Trial of Ofatumumab and Bendamustine Versus Ofatumumab, Bendamustine, and Bortezomib Induction and Maintenance Therapy in Patients (pts) with Previously Untreated High Risk Follicular Lymphoma (FL): Results from CALGB 50904 (Alliance)

Kristie A. Blum, MD, Sin-Ho Jung, PhD, Ian Barak, MS, Eric D. Hsi, MD, Nina D. Wagner-Johnston, MD, Beth Christian, MD, Jim Atkins, Bruce D. Cheson, MD, John P. Leonard, MD, Nancy L. Bartlett, MD

Blood (2017) 130 (Supplement 1): 485.

https://doi.org/10.1182/blood.V130.Suppl_1.485.485

Published: 2017

Journal Articles

Outcomes of Patients with Primary Refractory Mantle Cell Lymphoma, a Single Center Retrospective Study

David A Bond, MD, Ying Huang, MA, MS, Beth Christian, MD, Kami J. Maddocks, MD

Blood (2017) 130 (Supplement 1): 1503.

https://doi.org/10.1182/blood.V130.Suppl_1.1503.1503

Published: 2017

Journal Articles

A Phase I/II Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin’s Lymphoma (HL)

Beth Christian, MD, Lai Wei, Jennifer Sexton, Samantha M. Jaglowski, MD MPH, Steven M. Devine, MD, Todd A. Fehniger, MD PhD, Nina Wagner-Johnston, Nancy L. Bartlett, MD, Kristie A. Blum, MD

Blood (2014) 124 (21): 3099.

https://doi.org/10.1182/blood.V124.21.3099.3099

Published: 2014

Journal Articles

A Phase II Study of MLN8237 (Alisertib) Alone and in Combination with Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (NHL)

Kami J. Maddocks, MD, Jonathon B. Cohen, MD, Beth Christian, MD, Joseph M Flynn, DO, MPH, Samantha M. Jaglowski, MD MPH, Kristie A. Blum, MD

Blood (2014) 124 (21): 3082.

https://doi.org/10.1182/blood.V124.21.3082.3082

Published: 2014

Journal Articles

Poor Overall Survival of Patients with Ibrutinib-Resistant Mantle Cell Lymphoma

Peter Martin, MD, Kami J. Maddocks, MD, Katherine Noto, Beth Christian, MD, Richard R. Furman, MD, Leslie A. Andritsos, MD, Joseph M Flynn, D.O., MPH, Jeffrey A. Jones, MD, Jia Ruan, MD PhD, Selina Chen-Kiang, PhD, Maurizio Di Liberto, PhD, John P. Leonard, MD, Kristie A. Blum, MD

Blood (2014) 124 (21): 3047.

https://doi.org/10.1182/blood.V124.21.3047.3047

Published: 2014

Journal Articles

Poor Prognostic Effect of CD5 Positivity for Patients with Diffuse Large B-Cell Lymphoma: Results from a Retrospective Single Institution Analysis

Lapo Alinari, MD PhD, Alejandro Gru, MD, Carl Quinion, Ying Huang, PhD, Jeffrey A. Jones, MD, Steven M. Devine, MD, Kami J. Maddocks, MD, Beth Christian, MD, Robert A. Baiocchi, MD PhD, Kristie A. Blum, MD

Blood (2014) 124 (21): 1700.

https://doi.org/10.1182/blood.V124.21.1700.1700

Published: 2014

Journal Articles

A Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma

Beth Christian, MD, John Kuruvilla, MD, Sonali Smith, MD, Pierluigi Porcu, MD, Amy S. Ruppert, MAS, John C. Byrd, MD, Michael R. Grever, MD, Kristie A. Blum, MD

Blood (2014) 124 (21): 4476.

https://doi.org/10.1182/blood.V124.21.4476.4476

Published: 2014

Journal Articles

A Phase I Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)

Kristie A. Blum, MD, Beth Christian, MD, Joseph M. Flynn, DO, MPH, Samantha M. Jaglowski, MD, MPH, Jeffrey Alan Jones, MD, MPH, Kami Maddocks, MD, John C. Byrd, MD

Blood (2012) 120 (21): 1643.

https://doi.org/10.1182/blood.V120.21.1643.1643

Published: 2012

Journal Articles

A Phase I Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL)

Beth Christian, MD, Anne Kopko, Todd A. Fehniger, MD/PhD, Nancy L. Bartlett, MD, Kristie A. Blum, MD

Blood (2012) 120 (21): 1644.

https://doi.org/10.1182/blood.V120.21.1644.1644

Published: 2012

Journal Articles

Complex Karyotype (CK) Is Associated with a Shortened Progression-Free Survival (PFS) in Patients (pts) with Newly Diagnosed Mantle Cell Lymphoma (MCL).

Jonathon B. Cohen, MD, Amy S. Ruppert, MAS, Nyla A. Heerema, PhD, Jeffrey A. Jones, MD, MPH, Pierluigi Porcu, MD, Robert A. Baiocchi, M.D., Ph.D., Beth Christian, MD, John C. Byrd, MD, Joseph M. Flynn, DO, MPH, Sam Penza, MD, Leslie A Andritsos, MD, Steven M. Devine, MD, Kristie A. Blum, MD

Blood (2012) 120 (21): 2691.

https://doi.org/10.1182/blood.V120.21.2691.2691

Published: 2012

Journal Articles

Phase I Study of AR-42 in Relapsed Multiple Myeloma and Lymphoma.

Craig C. Hofmeister, MD, Zhongfa Liu, Ph.D., Mindy A Bowers, BS, Pierluigi Porcu, MD, Joseph M. Flynn, DO, MPH, Beth Christian, MD, Robert A. Baiocchi, M.D., Ph.D., Don M. Benson, Jr., MD, PhD, Leslie A Andritsos, MD, Carli N Greenfield, RN, MSN, ACNP, Megan Sell, RN, MS, Susan Geyer, PhD, John C. Byrd, MD, Michael R. Grever, MD

Blood (2012) 120 (21): 2955.

https://doi.org/10.1182/blood.V120.21.2955.2955

Published: 2012

Journal Articles

Complete Response (CR) to Induction Therapy in Patients (pts) with Myc+ and Double Hit Non-Hodgkin's Lymphoma (NHL) Is Associated with Prolonged Progression-Free Survival (PFS).

Jonathon B. Cohen, MD, Susan Geyer, PhD, Gerard Lozanski, M.D., Weiqiang Zhao, MD PhD, Nyla A. Heerema, PhD, Jeffrey A. Jones, MD, MPH, Pierluigi Porcu, MD, Beth Christian, MD, Robert A. Baiocchi, M.D., Ph.D., Kami Maddocks, MD, Joseph M. Flynn, DO, MPH, Steven M. Devine, MD, Kristie A. Blum, MD

Blood (2012) 120 (21): 2693.

https://doi.org/10.1182/blood.V120.21.2693.2693

Published: 2012

Journal Articles

Results of A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma,

Beth Christian, MD, Lapo Alinari, MD., Ph.D., Jeffrey A. Jones, MD, MPH, Don M Benson, Jr., MD, PhD, Joseph M. Flynn, DO, MPH, Pierluigi Porcu, MD, Mark E Lustberg, MD, PhD, Mitchell Phelps, Ph.D., Ming Poi, PharmD, PhD, Diana Chung, BS, Carl Quinion, John C. Byrd, MD, William Wegener, MD, PhD, David M Goldenberg, Robert A. Baiocchi, M.D., Ph.D., Kristie A. Blum, MD

Blood (2011) 118 (21): 3707.

https://doi.org/10.1182/blood.V118.21.3707.3707

Published: 2011

Journal Articles

Evidence of Long Latency Periods Prior to Development of Mantle Cell Lymphoma

Frederick Racke, MD, PhD, Sabrina Simpson, M.D., Beth Christian, MD, Kristie A. Blum, MD, Robert Hasserjian, MD, Weiqiang Zhao

Blood (2010) 116 (21): 323.

https://doi.org/10.1182/blood.V116.21.323.323

Published: 2010

Journal Articles

A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma.

Beth Christian, MD, Lapo Alinari, MD, Christian Tyler Earl, Emily Wilding, Carl Quinion, Mark Lustberg, MD, PhD, Don M Benson, Jr., MD, PhD, Jeffrey A. Jones, MD, MPH, John C. Byrd, MD, William A. Wegener, MD, PhD, David M. Goldenberg, ScD, MD, Robert A. Baiocchi, MD, PhD, Kristie A. Blum, MD

Blood (2010) 116 (21): 2788.

https://doi.org/10.1182/blood.V116.21.2788.2788

Published: 2010

Journal Articles

Flavopiridol Can Be Safely Administered Using a Pharmacologically Derived Schedule and Demonstrates Activity In Relapsed and Refractory Non-Hodgkin's Lymphoma.

Jeffrey A. Jones, MD, MPH, Leslie Andritsos, MD, Robert Baiocchi, MD, PhD, Don M Benson, Jr., MD, PhD, Kristie A. Blum, MD, Beth Christian, MD, Deidre Deam, RN, Joseph M. Flynn, DO, MPH, Amy J. Johnson, PhD, Mitch A. Phelps, PhD, Pierluigi Porcu, MD, John C. Byrd, MD, Michael R. Grever, M.D.

Blood (2010) 116 (21): 2834.

https://doi.org/10.1182/blood.V116.21.2834.2834

Published: 2010

Journal Articles

Co-Treatment with Milatuzumab (Anti-CD74 mAb) and Rituximab (Anti-CD20 mAb) Results in the Induction of Mantle Cell Lymphoma Cell Death That Is Dependent On Actin Polymerization and Inhibition of NF-Kb.

Lapo Alinari, MD, Beth Christian, MD, Bo Yu, Jungook Shin, Erin K Hertlein, PhD, Rosa Lapalombella, PhD, Fengting Yan, MD, PhD, Gregory Lesinski, PhD, Xiaoli Zhang, PhD, Gerard Lozanski, MD, Natarajan Muthusamy, PhD, David M. Goldenberg, ScD, MD, John C. Byrd, MD, Robert A. Baiocchi, MD, PhD

Blood (2009) 114 (22): 1694.

https://doi.org/10.1182/blood.V114.22.1694.1694

Published: 2009

NARROW

Efficacy and Safety of Pembrolizumab in Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (rrPMBCL): Updated Analysis of the Keynote-170 Phase 2 Trial

Randomized Phase 2 Trial of Ofatumumab and Bendamustine Versus Ofatumumab, Bendamustine, and Bortezomib Induction and Maintenance Therapy in Patients (pts) with Previously Untreated High Risk Follicular Lymphoma (FL): Results from CALGB 50904 (Alliance)

Outcomes of Patients with Primary Refractory Mantle Cell Lymphoma, a Single Center Retrospective Study

A Phase I/II Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin’s Lymphoma (HL)

A Phase II Study of MLN8237 (Alisertib) Alone and in Combination with Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (NHL)

Poor Overall Survival of Patients with Ibrutinib-Resistant Mantle Cell Lymphoma

Poor Prognostic Effect of CD5 Positivity for Patients with Diffuse Large B-Cell Lymphoma: Results from a Retrospective Single Institution Analysis

A Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma

A Phase I Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)

A Phase I Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL)

Complex Karyotype (CK) Is Associated with a Shortened Progression-Free Survival (PFS) in Patients (pts) with Newly Diagnosed Mantle Cell Lymphoma (MCL).

Phase I Study of AR-42 in Relapsed Multiple Myeloma and Lymphoma.

Complete Response (CR) to Induction Therapy in Patients (pts) with Myc+ and Double Hit Non-Hodgkin's Lymphoma (NHL) Is Associated with Prolonged Progression-Free Survival (PFS).

Results of A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma,

Evidence of Long Latency Periods Prior to Development of Mantle Cell Lymphoma

A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma.

Flavopiridol Can Be Safely Administered Using a Pharmacologically Derived Schedule and Demonstrates Activity In Relapsed and Refractory Non-Hodgkin's Lymphoma.

Co-Treatment with Milatuzumab (Anti-CD74 mAb) and Rituximab (Anti-CD20 mAb) Results in the Induction of Mantle Cell Lymphoma Cell Death That Is Dependent On Actin Polymerization and Inhibition of NF-Kb.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only